Gerhard Siemeister

This inventor holds 77 USPTO granted patents and 42 published patent applications, plus 15 CIPO patents and 55 EPO patents, primarily in Kinase Inhibitors (CPC class C07D). Top assignees: Bayer Pharma Aktiengesellschaft, Bayer Intellectual Property Gmbh, Schering Aktiengesellschaft. Active years: 2004-2024.

USPTO Granted Patents = 77 (Patent Applications = 42)

% Patents Active = 22.1

CIPO Patents = 15 (Patent Applications = 19)

EPO Patents = 55 (Patent Applications = 100)

Average Co-Inventor Count = 7.1

ph-index = 9

Forward Citations = 354(Granted Patents)

Forward Citations (Not Self Cited) = 296(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

38 out of 386

Bayer Pharma Aktiengesellschaft

patents

25 out of 721

Bayer Intellectual Property Gmbh

patents

9 out of 1,409

Schering Aktiengesellschaft

patents

4. 4 out of 192

Bayer Schering Pharma Ag

Bayer Aktiengesellschaft

patents

where one patent can have more than one assignee

Years Active: 2004-2024

Loading Chart...

Areas of Expertise:

ATR Kinase

BUB1 Inhibitors

Macrocyclic Compounds

Triazolopyridines

Sulfoximine

Naphthyridines

Prodrug Derivatives

Hyperproliferative Diseases

Sulfondiimine

Amino-Substituted

Fluorinated Derivatives

Substituted Benzylindazoles

77 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11976334 - Inhibitor of ATR kinase for use in a method of treating a hyper-proliferative disease (2024-05-07),

2. 11712440 - Predictive markers for ATR kinase inhibitors (2023-08-01),

3. 11660301 - Combination of ATR kinase inhibitors with PARP inhibitors (2023-05-30),

4. 11529356 - 2-(morpholin-4-yl)-1,7-naphthyridines (2022-12-20),

5. 10772893 - 2-(morpholin-4-yl)-1,7-naphthyridines (2020-09-15),

6. 10729680 - 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines (2020-08-04),

7. 10717749 - Macrocyclic sulfondiimine compounds (2020-07-21),

8. 10604532 - Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases (2020-03-31),

9. 10428063 - 4H-pyrrolo[3,2-C]pyridin-4-one derivatives (2019-10-01),

10. 10428044 - 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones (2019-10-01),

11. 10350206 - Benzyl substituted indazoles as BUB1 inhibitors (2019-07-16),

12. 10308629 - 1H-pyrrol-3-amines (2019-06-04),

13. 10266548 - Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases (2019-04-23),

14. 10227299 - 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones (2019-03-12),

15. 10214542 - Modified macrocyclic compounds (2019-02-26),

Certainly! Here is the article about inventor Gerhard Siemeister based on the data provided:

Title: The Innovations of Inventor Gerhard Siemeister

Introduction:

Gerhard Siemeister, a prolific inventor hailing from Berlin, Germany, has made significant contributions to the field of medicine with his groundbreaking patents.

Latest Patents:

Among his extensive portfolio of 76 patents, Gerhard Siemeister's latest innovations include predictive markers for ATR kinase inhibitors and the combination of ATR kinase inhibitors with PARP inhibitors for the treatment of hyper-proliferative diseases.

Career Highlights:

During his career, Gerhard Siemeister has worked with reputable companies such as Bayer Pharma Aktiengesellschaft and Bayer Intellectual Property GmbH, where he has honed his skills and expertise in developing novel therapeutics.

Collaborations:

Siemeister has collaborated closely with esteemed colleagues such as Philip Lienau and Ulrich Lücking, pooling their knowledge and experience to drive innovation in the pharmaceutical industry.

Conclusion:

Inventor Gerhard Siemeister's relentless pursuit of innovation and his groundbreaking patents in the field of medicine have significantly impacted the way hyper-proliferative diseases are treated, solidifying his legacy as a visionary in the world of medical research.

If you have any more specific requests or need further information, feel free to ask!